Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

Circulation (New York, N.Y.), 2013-05, Vol.127 (21), p.2114-2124 [Peer Reviewed Journal]

2013 American Heart Association, Inc. ;2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.113.001278 ;PMID: 23633271 ;CODEN: CIRCAZ

Full text available